Glenmark Pharmaceuticals Ltd (GLEN.NS)
(The following statement was released by the rating agency) SINGAPORE/MUMBAI, August 01 (Fitch) Fitch Ratings has assigned India-based Glenmark Pharmaceuticals Ltd's (Glenmark, BB/Positive) USD200m 4.50% senior unsecured notes due in 2021 a final rating of 'BB'. The final rating is in line with the expected rating assigned on 18 July 2016, and follows the receipt of final documents conforming to information already received. Glenmark will use the proceeds to repay debt at its wholly owned ov
(The following statement was released by the rating agency) SINGAPORE/MUMBAI, July 18 (Fitch) Fitch Ratings has assigned India-based Glenmark Pharmaceuticals Ltd (Glenmark) a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'BB'. The Outlook is Positive. Fitch has also assigned Glenmark's proposed Reg S notes an expected rating of 'BB(EXP)'. Glenmark's rating incorporates its geographically diversified profile, a demonstrated track record in regulatory compliance and its healthy pr
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Glenmark Pharmaceuticals Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.